Plant metal chaperones: A novel perspective in dementia therapy

Amyloid

Volumn 16, Issue 2, 2009, Pages 81-83

  Kastenholz, Bernd ^a   Garfin, David E ^b   Horst, Jürgen ^c   Nagel, Kerstin A ^a  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b American Electrophoresis Society   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

A ; Alzheimer's disease; Biochemical impact; CCS; Metal chaperones; SOD 1

Indexed keywords

AMYLOID BETA PROTEIN; CHAPERONE; CHOLINESTERASE INHIBITOR; CLIOQUINOL; COPPER; COPPER DERIVATIVE; CURCUMIN; MELATONIN; OROTATE COPPER; PLANT MEDICINAL PRODUCT; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALZHEIMER DISEASE; ARTICLE; BIOAVAILABILITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; COPPER BLOOD LEVEL; COPPER METABOLISM; DEMENTIA; HOMEOSTASIS; HUMAN; MYELOOPTIC NEUROPATHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT INDICATION;

COPPER; DEMENTIA; HOMEOSTASIS; HUMANS; MOLECULAR CHAPERONES; OXIDATIVE STRESS; PLANTS;

EID: 70849109616     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.1080/13506120902879392     Document Type: Article

References (10)

1. Pajonk F-G, Kessler H, Supprian T, Hamzei P, Bach D, Schweickhardt J, Herrmann W, Obeid R, Simons A, Falkai P, Multhaup G, Bayer TA. Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease. J Alz Dis 2005;8:23-27.
2. Kessler H. Bayer T.A. Bach D. Schneider-Axmann T. Supprian T. Herrmann W. Haber M. Multhaup G. Falkai P. Pajonk F.-G. Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: A pilot phase 2 clinical trial J Neural Transm 2008 115, 1181-1187
3. Kessler H, Bayer TA, Bach D, Schneider-Axmann T, Supprian T, Herrmann W, Haber M, Multhaup G, Falkai P, Pajonk F-G. Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. J Neural Transm 2008;115:1181-1187.3. Bayer TA, Multhaup G. Involvement of amyloid b precursor protein (Ab PP) modulated copper homeostasis in Alzheimer's disease. J Alz Dis 2005;8:201-206.
4. Thompson KH, Orvig C. Boon and bane of metal ions in medicine. Science 2003;300:936-939.
5. Crouch PJ, White AR, Bush AI. The modulation of metal bioavailability as a therapeutic strategy for the treatment of Alzheimer's disease. FEBS J 2007;274:3775-3783.
6. Doraiswamy PM, Finefrock AE. Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol 2004;3:431-434.
7. Gaggelli E, Kozlowski H, Valensin D, Valensin G. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev 2006;106:1995-2044.
8. Macreadie IG. Copper transport and Alzheimer's disease. Eur Biophys J 2008;37:295-300.
9. Rochet J-C. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev MolMed 2007;9:1-34.
10. Kastenholz B, Garfin DE. Medicinal plants: a natural chaperones source for treating neurological disorders. Protein Pept Lett 2009;16:116-120